Skip to NavigationSkip to content


Translational Neuroscience

Advancing Clinical Trials in CNS

ISN-ESN 2011

Cerovive failure another blow for AstraZeneca


A drug which had held out the promise of reducing the disabling effects of stroke on patients will be abandoned by AstraZeneca after it failed to show any significant benefits in trials.

The news is another blow to the company's pipeline, and adds to a string of major late-stage failures in recent years, including anti-clotting drug Exanta and cancer drug Tarceva.

AstraZeneca had licensed Cerovive (NXY-059) from US specialist pharma company Renovis, and had hoped the drug would boost its thin in-house pipeline.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches